Sevelamer carbonate reduces the risk of hypomagnesemia in hemodialysis-requiring end-stage renal disease patients

Clinical Kidney Journal

Volumn 9, Issue 3, 2016, Pages 481-485

  Rosa Diez, Guillermo ^a   Negri, Armando Luis ^b   Crucelegui, Maria Soledad ^a   Philippi, Romina ^a   Perez Teysseyre, Hernán ^a   Sarabia Reyes, Carmen ^a   Loor Navarrete, Henry ^a   Heguilen, Ricardo ^c  

^a HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^b UNIVERSIDAD DEL SALVADOR   (Argentina)

^c HOSPITAL JUAN A FERNÁNDEZ   (Argentina)

Author keywords

Hemodialysis; Hypomagnesemia; Proton pump inhibitors; Sevelamer

Indexed keywords

CALCIUM ACETATE; CALCIUM CARBONATE; CHOLESTEROL; MAGNESIUM; PARATHYROID HORMONE; PHOSPHATE; PHOSPHATE BINDING AGENT; PROTON PUMP INHIBITOR; SEVELAMER CARBONATE;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CROSS-SECTIONAL STUDY; END STAGE RENAL DISEASE; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPOMAGNESEMIA; MAGNESIUM BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBSERVATIONAL STUDY; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; RISK REDUCTION;

EID: 84979043530     PISSN: 20488505     EISSN: 20488513     Source Type: Journal    
DOI: 10.1093/ckj/sfw021     Document Type: Article

References (32)

1. Alhosaini M, Leehey DJ. Magnesium and dialysis: the neglected cation. Am J Kidney Dis 2015; 66: 523-531
2. Pham PC, Pham PM, Pham SV et al. Hypomagnesemia in patients with type 2 diabetes. Clin J Am Soc Nephrol 2007; 2: 366-373
3. Schulze MB, Schulz M, Heidemann C et al. Fiber and magnesium intake and incidence of type 2 diabetes: a prospective study and meta-analysis. Arch Intern Med 2007; 167: 956-965
4. Dickinson HO, Nicolson DJ, Campbell F et al. Magnesium supplementation for the management of essential hypertension in adults. Cochrane Database Syst Rev 2006; 3: CD004640
5. Jee SH, Miller ER III, Guallar E et al. The effect of magnesium supplementation on blood pressure: a meta-analysis of randomized clinical trials. Am J Hypertens 2002; 15: 691-696
6. Peacock JM, Folsom AR, Arnett DK et al. Relationship of serum and dietary magnesium to incident hypertension: the Atherosclerosis Risk in Communities (ARIC) Study. Ann Epidemiol 1999; 9: 159-165
7. Altura BM, Altura BT. New perspectives on the role of magnesium in the pathophysiology of the cardiovascular system. I. Clinical aspects. Magnesium 1985; 4: 226-244
8. Del Gobbo LC, Imamura F,Wu JH et al. Circulating and dietary magnesium and risk of cardiovascular disease: a systematic review and meta-analysis of prospective studies. Am J Clin Nutr 2013; 98: 160-173
9. Larsson SC, Orsini N,Wolk A. Dietary magnesium intake and risk of stroke: a meta-analysis of prospective studies. Am J Clin Nutr 2012; 95: 362-366
10. Liao F, Folsom AR, Brancati FL. Is low magnesium concentration a risk factor for coronary heart disease? The Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J 1998; 136: 480-490
11. Reffelmann T, Ittermann T, Dorr M et al. Low serum magnesium concentrations predict cardiovascular and all-cause mortality. Atherosclerosis 2011; 219: 280-284
12. Xu T, Sun Y, Xu T et al. Magnesium intake and cardiovascular disease mortality: a meta-analysis of prospective cohort studies. Int J Cardiol 2013; 167: 3044-3047
13. Pham PC, Pham PM, Pham PT et al. The link between lower serum magnesium and kidney function in patients with diabetes mellitus type 2 deserves a closerlook. Clin Nephrol 2009; 71: 375-379
14. Sakaguchi Y, Shoji T, Hayashi T et al. Hypomagnesemia in type 2 diabetic nephropathy: a novel predictor of end-stage renal disease. Diabetes Care 2012; 35: 1591-1597
15. Tin A, Grams ME, MaruthurNMet al. Results fromthe Atherosclerosis Risk in Communities study suggest that low serum magnesium is associated with incident kidney disease. Kidney Int 2015; 87: 820-827
16. Van Laecke S, Nagler EV, Verbeke F et al. Hypomagnesemia and the risk of death and GFR decline in chronic kidney disease. Am J Med 2013; 126: 825-831
17. Ishimura E, Okuno S, Yamakawa T et al. Serum magnesium concentration is a significant predictor of mortality in maintenance hemodialysis patients. Magnes Res 2007; 20: 237-244
18. Sakaguchi Y, Fujii N, Shoji T et al. Hypomagnesemia is a significant predictor of cardiovascular and non-cardiovascular mortality in patients undergoing hemodialysis. Kidney Int 2014; 85: 174-181
19. Li L, Streja E, Rhee CM et al. Hypomagnesemia and mortality in incident hemodialysis patients. Am J Kidney Dis 2015; 66: 1047-1055
20. Lacson E Jr,WangW, Ma L et al. Serum magnesium and mortality in hemodialysis patients in the United States: a cohort study. Am J Kidney Dis 2015; 66: 1056-1066
21. Konrad M, Schlingmann KP. Inherited disorders of renal hypomagnesaemia. Nephrol Dial Transplant 2014; 29 (Suppl 4): iv63-iv71
22. Schlingmann KP, Konrad M, Seyberth HW. Genetics of hereditary disorders of magnesium homeostasis. Pediatr Nephrol 2004; 19: 13-25
23. Alhosaini M, Walter JS, Singh S et al. Hypomagnesemia in hemodialysis patients: role of proton pump inhibitors. Am J Nephrol 2014; 39: 204-209
24. Misra PS, Alam A, Lipman ML et al. The relationship between proton pump inhibitor use and serum magnesium concentration among hemodialysis patients: a cross-sectional study. BMC Nephrol 2015; 16: 136
25. Mitsopoulos E, Griveas I, Zanos S et al. Increase in serum magnesiumlevel in haemodialysis patients receiving sevelamer hydrochloride. Int Urol Nephrol 2005; 37: 321-328
26. Bross R, Noori N, Kovesdy CP et al. Dietary assessment of individuals with chronic kidney disease. Semin Dial 2010; 23: 359-364
27. Rastogi A. Sevelamer revisited: pleiotropic effects on endothelial and cardiovascular risk factors in chronic kidney disease and end stage renal disease. Ther Adv Cardiovasc Dis 2013; 7: 322-342
28. Block GA, Spiegel DM, Ehrlich J et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005; 68: 1815-1824
29. Kakuta T, Tanaka R, Hyodo Tet al. Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients. Am J Kidney Dis 2011; 57: 422-431
30. Jamal SA, Vandermeer B, Raggi P et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet 2013; 382: 1268-1277
31. JoãoMatias P, Azevedo A, Laranjinha I et al. Lower serum magnesium is associated with cardiovascular risk factors and mortality in haemodialysis patients. Blood Purif 2014; 38: 244-252
32. Meema HE, Oreopoulos DG, Rapoport A. Serum magnesium level and arterial calcification in end-stage renal disease. Kidney Int 1987; 32: 388-394